Sciahbasi Alessandro, Mazza Tiziano Maria, Pidone Chiara, Samperi Simona, Cittadini Edoardo, Granatelli Antonino
Interventional Cardiology, Sandro Pertini Hospital-ASL RM2, 00157 Rome, Italy.
J Clin Med. 2024 Feb 26;13(5):1320. doi: 10.3390/jcm13051320.
: Drug-coated balloons (DCB) are a well-established option for treating in-stent restenosis endorsed by European Guidelines on myocardial revascularization. However, in recent years, a strategy of "leaving nothing behind" with DCB in de novo coronary stenosis has emerged as an appealing approach. : We performed a systematic review to evaluate the current literature on the use of drug-coated balloons in the treatment of de novo stenosis in large vessel disease. : Observational studies, as well as randomized studies, demonstrated the safety of DCB percutaneous coronary interventions (PCI) in large vessel disease. The rate of major adverse cardiac events is even lower compared to drug-eluting stents in stable coronary artery disease. : DCB PCI is feasible in large vessel disease, and future large, randomized studies are ongoing to confirm these results.
药物涂层球囊(DCB)是治疗支架内再狭窄的一种成熟选择,得到了欧洲心肌血运重建指南的认可。然而,近年来,在初发冠状动脉狭窄中采用DCB“不留任何东西”的策略已成为一种有吸引力的方法。:我们进行了一项系统评价,以评估目前关于药物涂层球囊用于治疗大血管疾病初发狭窄的文献。:观察性研究以及随机研究均证明了DCB经皮冠状动脉介入治疗(PCI)在大血管疾病中的安全性。在稳定型冠状动脉疾病中,主要不良心脏事件的发生率甚至低于药物洗脱支架。:DCB PCI在大血管疾病中是可行的,未来正在进行大型随机研究以证实这些结果。